Evidence for an association of co-medication and lyso-PCs with dose requirement in everolimus-based immunosuppression https://t.co/yT6YBLMB9v (#Metabolomics)
RT @metabolomics: Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophos…
Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement https://t.co/KjZ9D00yn4
Now published! https://t.co/f1gcYYaqu7
RT @DoroLesche: https://t.co/I3knL7U9mL @metabolomics Got insights into everolimus dose response in cardiac transplant patients using a pha…
Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement https://t.co/TrXXv0IOWd
https://t.co/I3knL7U9mL @metabolomics Got insights into everolimus dose response in cardiac transplant patients using a pharmacometabolomics approach. Big thanks to my colleagues @CNakas @Leichtle